Press Resease

Oncolytic Virus Immunotherapy Market - Global Industry Analysis

Oncolytic Virus Immunotherapy Market - By Application (Melanoma, Myeloma, Bladder Cancer, Ovarian Cancer, Prostrate Cancer, Lung Cancer, and Breast Cancer), By Product Type (HSV-based Oncolytic Viruses, Vaccinia Virus-based Oncolytic Viruses, Adenovirus-based Oncolytic Viruses, Newcastle Disease Virus-based Oncolytic Viruses, and Vesicular Stomatitis Virus-based Oncolytic Viruses), And By Region- Global Industry Perspective, Comprehensive Analysis, and Forecast, 2021 – 2028

Published Date: 13-Aug-2021 Category: Pharmaceutical Report Format : PDF Pages: 150 Report Code: ZMR-6593 Status : Published

The global Oncolytic Virus Immunotherapy market accrued earnings worth approximately301 (USD Million) in 2020 and is predicted to gain revenue of about 678(USD Million) by 2028, is set to record a CAGR of nearly 12.1% over the period from 2021 to 2028.

Description

The global Oncolytic Virus Immunotherapy market accrued earnings worth approximately301 (USD Million) in 2020 and is predicted to gain revenue of about 678(USD Million) by 2028, is set to record a CAGR of nearly 12.1% over the period from 2021 to 2028. The report offers assessment and analysis of the Oncolytic Virus Immunotherapy market on a global and regional level. The study offers a comprehensive assessment of the market competition, constraints, revenue estimates, opportunities, evolving trends, and industry-validated data. The report provides historical data from 2018 to 2020 along with a forecast from 2021 to 2028 based on revenue (USD Million).

Report Scope :

Report Attribute Details
Base Year 2020
Historic Years 2016 - 2020
Forecast Years 2021 - 2028
Segments Covered By Product Type, By Application, and By End Use
Forecast Units Value (USD Billion), and Volume (Units)
Quantitative Units Revenue in USD million/billion and CAGR from 2021 to 2028
Regions Covered North America, Europe, Asia Pacific, Latin America, and Middle East & Africa, and Rest of World
Countries Covered U.S., Canada, Mexico, U.K., Germany, France, Italy, Spain, China, India, Japan, South Korea, Brazil, Argentina, GCC Countries, and South Africa, among others
Number of Companies Covered 10 companies with scope for including additional 15 companies upon request
Report Coverage Market growth drivers, restraints, opportunities, Porter’s five forces analysis, PEST analysis, value chain analysis, regulatory landscape, market attractiveness analysis by segments and region, company market share analysis, and COVID-19 impact analysis.
Customization Scope Avail customized purchase options to meet your exact research needs.

Oncolytic Virus Immunotherapy Market: Synopsis

Oncolytic virus is a new therapy for treating cancer and it can infect & destroy cancer tissues, thereby acting as in situ cancer vaccine by releasing tumor-specific antigens. Precisely, oncolytic viruses are class of therapeutic agents prompting anti-tumor responses through selectively killing of cell tumors along with inducing of systemic anti-tumor immunization. Reportedly, oncolytic viruses can help in stimulating immune responses of host cells against cancer. Furthermore, oncolytic virus immunotherapy is a novel approach in cancer treatment making use of genetically modified viruses selectively replicating in tumors. Though ability of virus in killing cancer cells has been known long back, clinical trials documenting its therapeutic benefits on cancer patients has been recorded during past decade. With comprehensive knowledge about viral biology, molecular genetics, and tumor immunology, there has been immense interest in ongoing research activities pertaining to application of oncolytic viruses in treating cancer.  For the record, in October 2015, virus referred as T-VEC or talimogene laherparepvec was the first oncolytic virus immunotherapy approved by U.S. FDA for cancer treatment. Furthermore, success of T-VEC has prompted new drug discovery for treating cancer. Additionally, H101- a genetically modified oncolytic adenovirus- used in combination with chemotherapy was approved by Chinese government for treating nasopharyngeal carcinoma in November 2005.

Additionally, oncolytic viruses make use of two mechanisms for treating tumors, namely, selective replicating of viruses within neoplastic cells leading to direct lytic effect on cell tumors and inducting of systemic anti-tumor immunity in human system. Developing of oncolytic viruses as drugs for treating various kinds of cancer is predicted to help market explore new areas of growth in healthcare sector in next few years.

Oncolytic Virus Immunotherapy Market: Growth Drivers

Immunotherapy is a leading treatment in oncology with myriad therapies targeting tumor biology and oncolytic virus immunotherapy being one of the most promising ones. Additionally, the latter provides multimodal approach for effectively targeting & killing malignant tumors. This has resulted in massive use of oncolytic virus immunotherapy in cancer treatment, thereby driving market trends. Apparently, oncolytic virus immunotherapy is tailored for particular cell targets at specific locations and this is projected to have long lasting impact on drug molecule development for cancer treatment. It has been found that oncolytic virus immunotherapy has the ability for inducing potent anti-tumoural effects that help in eliminating cancerous tissues and this has create a massive hype and demand for oncolytic virus immunotherapy in healthcare sector. Moreover, tumor specific oncolytic viruses have proved to be new anticancer agents and its efficacy is being tested intensely in phase I and phase III clinical trials. All these moves and aforementioned factors are projected to be key growth drivers for oncolytic virus immunotherapy market in near future.

Additionally, insights into mechanisms of virus replication, entry, induction, and immune response suppression has resulted into utilization of virus for treating human ailments along with choosing of oncolytic viral vectors for treatment of particular kinds of cancers. This will translate into charting of new growth path for oncolytic virus immunotherapy market in coming decade. Furthermore, oncolytic viruses provide danger signals promoting proficient anti-tumor immune responses in humans. Ability of counteracting cancer mediated immune evasion will steer growth of oncolytic virus immunotherapy industry during forecast timeframe.

Regional Landscape

North America To Make Notable Contributions Towards Overall Market Size By 2028

The expansion of oncolytic virus immunotherapy market in North America is owing to rise in cases of cancer in North America. Additionally, large-scale presence of giant manufacturers & vendors in the U.S. and Canada will contribute lucratively towards regional market proceeds. Huge government funding of research activities related to novel therapies for cancer treatment & new drug development will proliferate size of oncolytic virus immunotherapy market in North America. Apparently, oncolytic virus immunotherapy industry is likely to experience huge growth prospects in sub-continent due to large proportion of sponsorships from cancer drug molecule manufacturers of the region.

Competitive Landscape

Key players profiled in study include Amgen, Inc., Genelux Corporation, Cold Genesys, Inc., Lokon Pharma AB, Takara Bio, Viralytics Ltd., Shanghai Sunway Biotech, Oncolytics Biotech, Inc., DNAtrix Therapeutics, Transgene sa, Turnstone Biologics, VCN Biosciences, and Vyriad.

The global Oncolytic Virus Immunotherapy Market is segmented as follows:

By Application

  • Melanoma
  • Bladder Cancer
  • Ovarian Cancer
  • Prostrate Cancer
  • Lung Cancer
  • Breast Cancer
  • Myeloma

By Product Type

  • HSV-based Oncolytic Viruses
  • Vaccinia Virus-based Oncolytic Viruses
  • Adenovirus-based Oncolytic Viruses
  • Newcastle Disease Virus-based Oncolytic Viruses
  • Vesicular Stomatitis Virus-based Oncolytic Viruses

By Region

  • North America
    • The U.S.
    • Canada
  • Europe
    • France
    • The UK
    • Spain
    • Germany
    • Italy
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • GCC
    • South Africa
    • Rest of Middle East & Africa

Table Of Content

  • Chapter 1. Preface
    • 1.1. Report Description and Scope
    • 1.2. Research Scope
    • 1.3. Research Methodology
      • 1.3.1. Market Research Type
      • 1.3.2. Market Research Methodology
  • Chapter 2. Executive Summary
    • 2.1. Onculytic Virus Immunotherapy Market, 2018–2028(USD Million)
    • 2.2. Onculytic Virus Immunotherapy Market: Snapshot
  • Chapter 3. Global Onculytic Virus Immunotherapy Market– Industry Analysis
    • 3.1. Onculytic Virus Immunotherapy Market: Market Dynamics
    • 3.2. Market Drivers
      • 3.2.1. Insights into mechanisms of virus replication, entry, induction, and immune response suppression has led to use of virus for treating human diseases along with selecting onculytic viral vectors for treating specific type of cancers. This will boost growth of onculytic virus immunotherapy market in coming years.
      • 3.2.2. Immunotherapy is a major onculogy therapy targeting tumor biulogy and onculytic virus immunotherapy being most prominent among it. Additionally, the latter provides multimodal approach for effectively killing malignant cancer cells. This has resulted in humungous utility of onculytic virus immunotherapy in treating cancer, thereby driving industry trends.
    • 3.3. Porter’s Five Forces Analysis
    • 3.4. Market Attractiveness Analysis
      • 3.4.1. Market attractiveness analysis By Application
      • 3.4.2. Market attractiveness analysis By Product Type
  • Chapter 4. Global Onculytic Virus Immunotherapy Market– Competitive Landscape
    • 4.1. Company market share analysis
      • 4.1.1. Global Onculytic Virus Immunotherapy Market: company market share, 2019
    • 4.2. Strategic development
      • 4.2.1. Acquisitions & mergers
      • 4.2.2. New Product launches
      • 4.2.3. Agreements, partnerships, cullaborations, and joint ventures
      • 4.2.4. Research and development and Regional expansion
    • 4.3. Price trend analysis
  • Chapter 5. Global Onculytic Virus Immunotherapy Market– Application Analysis
    • 5.1. Global Onculytic Virus Immunotherapy Market overview: By Application
      • 5.1.1. Global Onculytic Virus Immunotherapy Market share, By Application, 2020 and 2028
    • 5.2. Melanoma
      • 5.2.1. Global Onculytic Virus Immunotherapy Market by Melanoma, 2018–2028(USD Million)
    • 5.3. Myeloma
      • 5.3.1. Global Onculytic Virus Immunotherapy Market by Myeloma, 2018–2028(USD Million)
    • 5.4. Bladder Cancer
      • 5.4.1. Global Onculytic Virus Immunotherapy Market by Bladder Cancer, 2018–2028(USD Million)
    • 5.5. Prostrate Cancer
      • 5.5.1. Global Onculytic Virus Immunotherapy Market by Prostrate Cancer, 2018–2028(USD Million)
    • 5.6. Ovarian Cancer
      • 5.6.1. Global Onculytic Virus Immunotherapy Market by Ovarian Cancer, 2018–2028(USD Million)
    • 5.7. Culorectal Cancer
      • 5.7.1. Global Onculytic Virus Immunotherapy Market by Culorectal Cancer, 2018–2028(USD Million)
    • 5.8. Lung Cancer
      • 5.8.1. Global Onculytic Virus Immunotherapy Market by Lung Cancer, 2018–2028(USD Million)
    • 5.9. Breast Cancer
      • 5.9.1. Global Onculytic Virus Immunotherapy Market by Breast Cancer, 2018–2028(USD Million)
  • Chapter 6. Global Onculytic Virus Immunotherapy Market– Product Type Analysis
    • 6.1. Global Onculytic Virus Immunotherapy Market overview: By Product Type
      • 6.1.1. Global Onculytic Virus Immunotherapy Market share, By Product Type, 2020 and 2028
    • 6.2. HSV-based Onculytic Viruses
      • 6.2.1. Global Onculytic Virus Immunotherapy Market by HSV-based Onculytic Viruses, 2018–2028(USD Million)
    • 6.3. Vaccinia Virus-based Onculytic Viruses
      • 6.3.1. Global Onculytic Virus Immunotherapy Market by Vaccinia Virus-based Onculytic Viruses, 2018–2028(USD Million)
    • 6.4. Vesicular Stomatitis Virus-based Onculytic Viruses
      • 6.4.1. Global Onculytic Virus Immunotherapy Market by Vesicular Stomatitis Virus-based Onculytic Viruses, 2018–2028(USD Million)
    • 6.5. Newcastle Disease Virus-based Onculytic Viruses
      • 6.5.1. Global Onculytic Virus Immunotherapy Market by Newcastle Disease Virus-based Onculytic Viruses, 2018–2028(USD Million)
    • 6.6. Adenovirus-based Onculytic Viruses
      • 6.6.1. Global Onculytic Virus Immunotherapy Market by Adenovirus-based Onculytic Viruses, 2018–2028(USD Million)
  • Chapter 7. Company Profiles
    • 7.1. Amgen, Inc.
      • 7.1.1. Overview
      • 7.1.2. Financials
      • 7.1.3. Product Portfolio
      • 7.1.4. Business Strategy
      • 7.1.5. Recent Developments
    • 7.2. Genelux Corporation
      • 7.2.1. Overview
      • 7.2.2. Financials
      • 7.2.3. Product Portfolio
      • 7.2.4. Business Strategy
      • 7.2.5. Recent Developments
    • 7.3. Culd Genesys, Inc.
      • 7.3.1. Overview
      • 7.3.2. Financials
      • 7.3.3. Product Portfolio
      • 7.3.4. Business Strategy
      • 7.3.5. Recent Development
    • 7.4. Lokon Pharma AB
      • 7.4.1. Overview
      • 7.4.2. Financials
      • 7.4.3. Product Portfolio
      • 7.4.4. Business Strategy
      • 7.4.5. Recent Development
    • 7.5. Takara Bio
      • 7.5.1. Overview
      • 7.5.2. Financials
      • 7.5.3. Product Portfolio
      • 7.5.4. Business Strategy
      • 7.5.5. Recent Development
    • 7.6. Viralytics Ltd.
      • 7.6.1. Overview
      • 7.6.2. Financials
      • 7.6.3. Product Portfolio
      • 7.6.4. Business Strategy
      • 7.6.5. Recent Development
    • 7.7. Shanghai Sunway Biotech
      • 7.7.1. Overview
      • 7.7.2. Financials
      • 7.7.3. Product Portfolio
      • 7.7.4. Business Strategy
      • 7.7.5. Recent Development
    • 7.8. Onculytics Biotech, Inc.
      • 7.8.1. Overview
      • 7.8.2. Financials
      • 7.8.3. Product Portfolio
      • 7.8.4. Business Strategy
      • 7.8.5. Recent Development
    • 7.9. Vyriad
      • 7.9.1. Overview
      • 7.9.2. Financials
      • 7.9.3. Product Portfolio
      • 7.9.4. Business Strategy
      • 7.9.5. Recent Development
    • 7.10. VCN Biosciences
      • 7.10.1. Overview
      • 7.10.2. Financials
      • 7.10.3. Product Portfolio
      • 7.10.4. Business Strategy
      • 7.10.5. Recent Development
    • 7.11. Turnstone Biulogics
      • 7.11.1. Overview
      • 7.11.2. Financials
      • 7.11.3. Product Portfolio
      • 7.11.4. Business Strategy
      • 7.11.5. Recent Development
    • 7.12. Transgene sa
      • 7.12.1. Overview
      • 7.12.2. Financials
      • 7.12.3. Product Portfolio
      • 7.12.4. Business Strategy
      • 7.12.5. Recent Development
    • 7.13. DNAtrix Therapeutics
      • 7.13.1. Overview
      • 7.13.2. Financials
      • 7.13.3. Product Portfolio
      • 7.13.4. Business Strategy
      • 7.13.5. Recent Development

List of Figures

1. Market research Type
2. Market research methodology
3. Global Oncolytic Virus Immunotherapy Market, 2018–2028(USD Million)
4. Porter’s Five Forces Analysis
5. Global Oncolytic Virus Immunotherapy Marketattractiveness, By Application
6. Global Oncolytic Virus Immunotherapy Marketattractiveness, By Product Type
7. Global Oncolytic Virus Immunotherapy Marketshare by Application ,2020 and 2028 (USD Million)
8. Global Oncolytic Virus Immunotherapy Marketby Melanoma, 2018–2028(USD Million)
9. Global Oncolytic Virus Immunotherapy Marketby Myeloma, 2018–2028(USD Million)
10. Global Oncolytic Virus Immunotherapy Marketby Bladder Cancer, 2018–2028(USD Million)
11. Global Oncolytic Virus Immunotherapy Marketby Prostrate Cancer, 2018–2028(USD Million)
12. Global Oncolytic Virus Immunotherapy Marketby Ovarian Cancer, 2018–2028(USD Million)
13. Global Oncolytic Virus Immunotherapy Marketby Breast Cancer, 2018–2028(USD Million)
14. Global Oncolytic Virus Immunotherapy Marketby Lung Cancer, 2018–2028(USD Million)
15. Global Oncolytic Virus Immunotherapy Marketshare by Product Type ,2020 and 2028 (USD Million)
16. Global Oncolytic Virus Immunotherapy Marketby HSV-based Oncolytic Viruses, 2018–2028(USD Million)
17. Global Oncolytic Virus Immunotherapy Marketby Vaccinia Virus-based Oncolytic Viruses, 2018–2028(USD Million)
18. Global Oncolytic Virus Immunotherapy Marketby Vesicular Stomatitis Virus-based Oncolytic Viruses, 2018–2028(USD Million)
19. Global Oncolytic Virus Immunotherapy Marketby Newcastle Disease Virus-based Oncolytic Viruses, 2018–2028(USD Million)
20. Global Oncolytic Virus Immunotherapy Marketby Adenovirus-based Oncolytic Viruses, 2018–2028(USD Million)
21. Global Oncolytic Virus Immunotherapy Marketshare, by Region, 2020 and 2028
22. North America Oncolytic Virus Immunotherapy Market, 2018–2028(USD Million)
23. Europe Oncolytic Virus Immunotherapy Market, 2018–2028(USD Million)
24. Asia Pacific Oncolytic Virus Immunotherapy Market, 2018–2028(USD Million)
25. Latin America Oncolytic Virus Immunotherapy Market, 2018–2028(USD Million)
26. The Middle East and Africa Oncolytic Virus Immunotherapy Market, 2018–2028(USD Million)


List of Tables

1. Global Oncolytic Virus Immunotherapy Market: snapshot
2. Drivers of the Oncolytic Virus Immunotherapy Market: impact analysis
3. North America Oncolytic Virus Immunotherapy Market revenue, By Application  ,2018–2028(USD Million)
4. North America Oncolytic Virus Immunotherapy Market revenue, By Product Type  ,2018–2028(USD Million)
5. The U.S. Oncolytic Virus Immunotherapy Market revenue, By Application  ,2018–2028(USD Million)
6. The U.S. Oncolytic Virus Immunotherapy Market revenue, By Product Type  ,2018–2028(USD Million)
7. Rest of North America Oncolytic Virus Immunotherapy Market revenue, By Application  ,2018–2028(USD Million)
8. Rest of North America Oncolytic Virus Immunotherapy Market revenue, By Product Type  ,2018–2028(USD Million)
9. Europe Oncolytic Virus Immunotherapy Market revenue, By Application  ,2018–2028(USD Million)
10. Europe Oncolytic Virus Immunotherapy Market revenue, By Product Type  ,2018–2028(USD Million)
11. UK Oncolytic Virus Immunotherapy Market revenue, By Application  ,2018–2028(USD Million)
12. UK Oncolytic Virus Immunotherapy Market revenue, By Product Type  ,2018–2028(USD Million)
13. France Oncolytic Virus Immunotherapy Market revenue, By Application  ,2018–2028(USD Million)
14. France Oncolytic Virus Immunotherapy Market revenue, By Product Type  ,2018–2028(USD Million)
15. Germany Oncolytic Virus Immunotherapy Market revenue, By Application  ,2018–2028(USD Million)
16. Germany Oncolytic Virus Immunotherapy Market revenue, By Product Type  ,2018–2028(USD Million)
17. Rest of Europe Oncolytic Virus Immunotherapy Market revenue, By Application  ,2018–2028(USD Million)
18. Rest of Europe Oncolytic Virus Immunotherapy Market revenue, By Product Type  ,2018–2028(USD Million)
19. Asia Pacific Oncolytic Virus Immunotherapy Market revenue, By Application  ,2018–2028(USD Million)
20. Asia Pacific Oncolytic Virus Immunotherapy Market revenue, By Product Type  ,2018–2028(USD Million)
21. China Oncolytic Virus Immunotherapy Market revenue, By Application  ,2018–2028(USD Million)
22. China Oncolytic Virus Immunotherapy Market revenue, By Product Type  ,2018–2028(USD Million)
23. Japan Oncolytic Virus Immunotherapy Market revenue, By Application  ,2018–2028(USD Million)
24. Japan Oncolytic Virus Immunotherapy Market revenue, By Product Type  ,2018–2028(USD Million)
25. India Oncolytic Virus Immunotherapy Market revenue, By Application  ,2018–2028(USD Million)
26. India Oncolytic Virus Immunotherapy Market revenue, By Product Type  ,2018–2028(USD Million)
27. Rest of Asia Pacific Oncolytic Virus Immunotherapy Market revenue, By Application  ,2018–2028(USD Million)
28. Rest of Asia Pacific Oncolytic Virus Immunotherapy Market revenue, By Product Type  ,2018–2028(USD Million)
29. Latin America Oncolytic Virus Immunotherapy Market revenue, By Application  ,2018–2028(USD Million)
30. Latin America Oncolytic Virus Immunotherapy Market revenue, By Product Type  ,2018–2028(USD Million)
31. Brazil Oncolytic Virus Immunotherapy Market revenue, By Application  ,2018–2028(USD Million)
32. Brazil Oncolytic Virus Immunotherapy Market revenue, By Product Type  ,2018–2028(USD Million)
33. Rest of Latin America Oncolytic Virus Immunotherapy Market revenue, By Application  ,2018–2028(USD Million)
34. Rest of Latin  America Oncolytic Virus Immunotherapy Market revenue, By Product Type  ,2018–2028(USD Million)
35. The Middle East and Africa Oncolytic Virus Immunotherapy Market revenue, By Application  ,2018–2028(USD Million)
36. The Middle East and Africa Oncolytic Virus Immunotherapy Market revenue, By Product Type  ,2018–2028(USD Million)
37. Saudi Arabia Oncolytic Virus Immunotherapy Market revenue, By Application  ,2018–2028(USD Million)
38. Saudi Arabia Oncolytic Virus Immunotherapy Market revenue, By Product Type  ,2018–2028(USD Million)
39. South Africa Oncolytic Virus Immunotherapy Market revenue, By Application  ,2018–2028(USD Million)
40. South Africa Oncolytic Virus Immunotherapy Market revenue, By Product Type  ,2018–2028(USD Million)
41. Rest of the Middle East & Africa Oncolytic Virus Immunotherapy Market revenue, By Application  ,2018–2028(USD Million)
42. Rest of the Middle East & Africa Oncolytic Virus Immunotherapy Market revenue, By Product Type  ,2018–2028(USD Million)

 
 

Methodology

Choose License Type

Request the coronavirus impact analysis across industries and markets

FrequentlyAsked Questions

Immunotherapy is a leading treatment in oncology with myriad therapies targeting tumor biology and oncolytic virus immunotherapy being one of the most promising ones. Additionally, the latter provides multimodal approach for effectively targeting & killing malignant tumors. This has resulted in massive use of oncolytic virus immunotherapy in cancer treatment, thereby driving market trends. Apparently, oncolytic virus immunotherapy is tailored for particular cell targets at specific locations and this is projected to have long lasting impact on drug molecule development for cancer treatment. It has been found that oncolytic virus immunotherapy has the ability for inducing potent anti-tumoural effects that help in eliminating cancerous tissues and this has create a massive hype and demand for oncolytic virus immunotherapy in healthcare sector. Moreover, tumor specific oncolytic viruses have proved to be new anticancer agents and its efficacy is being tested intensely in phase I and phase III clinical trials. All these moves and aforementioned factors are projected to be key growth drivers for oncolytic virus immunotherapy market in near future.

Additionally, insights into mechanisms of virus replication, entry, induction, and immune response suppression has resulted into utilization of virus for treating human ailments along with choosing of oncolytic viral vectors for treatment of particular kinds of cancers. This will translate into charting of new growth path for oncolytic virus immunotherapy market in coming decade.  

According to Zion market research report, the global Oncolytic Virus Immunotherapy market accrued earnings worth approximately301 (USD Million) in 2020 and is predicted to gain revenue of about 678(USD Million) by 2028, is set to record a CAGR of nearly 12.1% over the period from 2021 to 2028.

North America will contribute lucratively towards the global market size over the estimated timeline. The regional market surge is due to rise in cases of cancer in North America. Additionally, large-scale presence of giant manufacturers & vendors in the U.S. and Canada will contribute lucratively towards regional market proceeds. Huge government funding of research activities related to novel therapies for cancer treatment & new drug development will proliferate size of oncolytic virus immunotherapy market in North America. Apparently, oncolytic virus immunotherapy industry is likely to experience huge growth prospects in sub-continent due to large proportion of sponsorships from cancer drug molecule manufacturers of the region.

The key market participants include Amgen, Inc., Genelux Corporation, Cold Genesys, Inc., Lokon Pharma AB, Takara Bio, Viralytics Ltd., Shanghai Sunway Biotech, Oncolytics Biotech, Inc., DNAtrix Therapeutics, Transgene sa, Turnstone Biologics, VCN Biosciences, and Vyriad.

HappyClients

Office Address

Corporate Office

Zion Market Research 244 Fifth Avenue, Suite N202 New York, 10001, United States
Tel: +1 (844) 845-5245
USA/Canada Toll Free No.+1 (855) 465-4651

Asia Pacific Office

3rd Floor, Mrunal Paradise, Opp Maharaja Hotel, Pimple Gurav, Pune 411061, Maharashtra, India
Phone No 020-46277770

Contact #

US OFFICE NO +1 (844) 845-5245
US/CAN TOLL FREE +1 (855) 465-4651
Email: sales@zionmarketresearch.com

We Are On Social